Ashley R Lins from 5900 Gates Mill Pl, Midlothian, VA 23112, age 45, Phone: 804 639-4212

Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use
view source
US Patent:

7989472, Aug 2, 2011
Filed:

Mar 19, 2007
Appl. No.:

12/225056
Inventors:

Ronald M. Kim - Summit NJ, US
Emma R. Parmee - Scotch Plains NJ, US
Qiang Tan - Westfield NJ, US
Ashley Rouse Lins - Edison NJ, US
Jiang Chang - Westfield NJ, US
Cangming Yang - Highland Park NJ, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 31/47
A61K 31/4184
C07D 215/00
C07D 235/04
US Classification:

514311, 546112, 546152, 546174, 546175, 5483027, 5483097, 548469, 548510, 548217, 514299, 514385, 514394
Abstract:

Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Niacin Receptor Agonists, Compositions Containing Such Compounds And Methods Of Treatment
view source
US Patent:

8168649, May 1, 2012
Filed:

Jun 26, 2006
Appl. No.:

11/922629
Inventors:

Subharekha Raghavan - Teaneck NJ, US
Steven L. Colletti - Princeton Junction NJ, US
Hong Shen - West Windsor NJ, US
James R. Tata - Westfield NJ, US
Ashley Rouse Lins - Edison NJ, US
Abigail Lee Smenton - Brooklyn NY, US
Weichun Chen - Livingston NJ, US
Darby Rye Schmidt - Clark NJ, US
George Scott Tria - La Jolla CA, US
Assignee:

Merk Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 31/44
A01N 43/40
A61K 31/19
A61K 31/165
US Classification:

514292, 514338, 514364, 514568, 514617
Abstract:

The present invention encompasses compounds of Formula (I): as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.

Niacin Receptor Agonists, Compositions Containing Such Compounds And Methods Of Treatment
view source
US Patent:

20060293364, Dec 28, 2006
Filed:

Jun 26, 2006
Appl. No.:

11/474646
Inventors:

Subharekha Raghavan - Teaneck NJ, US
Steven Colletti - Princeton Junction NJ, US
Hong Shen - West Windsor NJ, US
James Tata - Westfield NJ, US
Ashley Lins - Edison NJ, US
Abigail Smenton - Brooklyn NY, US
Weichun Chen - Livingston NJ, US
Darby Schmidt - Clark NJ, US
George Tria - La Jolla CA, US
International Classification:

A61K 31/4439
A61K 31/43
A61K 31/427
A61K 31/4245
A61K 31/416
A61K 31/4192
A61K 31/35
A61K 31/195
US Classification:

514341000, 514365000, 514366000, 514379000, 514469000, 514563000, 548151000, 548202000, 548253000, 548240000, 562450000, 514406000, 548375100, 546269100, 514459000, 514359000
Abstract:

The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.

Niacin Receptor Agonists, Compositions Containing Such Compounds And Methods Of Treatment
view source
US Patent:

20090042926, Feb 12, 2009
Filed:

Dec 20, 2006
Appl. No.:

12/086938
Inventors:

Jason Imbriglio - Piscataway NJ, US
Steven L. Colletti - Princeton Junction NJ, US
James R. Tata - Westfield NJ, US
Richard T. Beresis - Matawan NJ, US
Daria Marley - Raleigh NC, US
Subharekha Raghavan - Teaneck NJ, US
Darby Rye Schmidt - Clark NJ, US
Ashley Rouse Lins - Edison NJ, US
Abigail L. Smenton - Brooklyn NJ, US
Weichun Chen - Livingston NJ, US
Hong Shen - West Windsor NJ, US
Rena Bodner - New York NY, US
International Classification:

A61K 31/4439
C07C 229/34
C07D 277/22
C07D 271/06
C07D 413/04
A61K 31/437
A61P 9/10
A61P 3/10
C07D 471/04
A61K 31/196
A61K 31/426
A61K 31/4245
US Classification:

514293, 562457, 548204, 548131, 5462694, 546 86, 514563, 514365, 514364, 514340
Abstract:

The present invention encompasses compounds of Formula (I): as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.

Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use
view source
US Patent:

20090105310, Apr 23, 2009
Filed:

May 11, 2007
Appl. No.:

12/227030
Inventors:

Ronald M. Kim - Summit NJ, US
Emma R. Parmee - Scotch Plains NJ, US
Qiang Tan - Westfield NJ, US
Cangming Yang - Highland Park NJ, US
Ashley Rouse Lins - Edison NJ, US
International Classification:

A61K 31/4402
C07D 471/02
C07C 63/33
C07D 211/76
A61K 31/44
A61P 3/04
C07D 215/18
A61K 31/495
A61K 31/19
US Classification:

514351, 544350, 562492, 546300, 546180, 514249, 514569, 514277
Abstract:

Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Niacin Receptor Agonists, Compositions Containing Such Compounds And Methods Of Treatment
view source
US Patent:

20120178750, Jul 12, 2012
Filed:

Mar 19, 2012
Appl. No.:

13/423618
Inventors:

Subharekha Raghavan - Teaneck NJ, US
Steven L. Colletti - Princeton Junction NJ, US
Hong Shen - West Windsor NJ, US
James R. Tata - West Windsor NJ, US
Ashley Rouse Lins - Midlothian VA, US
Abigail Lee Smenton - Edison NJ, US
Weichun Chen - Livingston NJ, US
Darby Rye Schmidt - Clark NJ, US
George Scott Tria - Princeton NJ, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 31/4439
A61K 31/423
A61K 31/429
A61K 31/41
A61K 31/426
A61K 31/427
A61K 31/403
A61K 31/4375
A61K 31/437
A61K 31/538
A61K 31/4196
A61P 9/10
A61P 3/06
A61P 3/10
A61P 3/00
A61K 31/196
US Classification:

5142305, 514563, 514379, 514366, 514381, 514365, 514340, 514341, 514411, 514292, 514294, 514383
Abstract:

The present invention encompasses compounds of Formula I:as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.

Ashley R Lins